Catalent | CTLT - Operating Profit


Catalent reported $-67M in Operating Profit for its fiscal quarter ending in September of 2024.



Operating Profit Change Date
Agilent USD 443M 66M Sep/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Bruker USD 76.3M 7.6M Dec/2025
Centene USD -1.23B 1.03B Dec/2025
Charles River Laboratories USD 133.8M 1.46M Sep/2025
Cigna USD 2.75B 240M Sep/2025
Danaher USD 1.5B 348M Dec/2025
Dentsply International USD 512M 401M Sep/2025
Elevance Health USD 581M 1.18B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Hologic USD 237M 16M Dec/2025
Humana USD -808M 1.21B Dec/2025
Illumina USD 256M 6M Dec/2025
Intuitive Surgical USD 865.3M 97.5M Dec/2025
IQVIA Holdings USD 2.68B 2.1B Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Laboratory Of America USD 397.3M 65.5M Sep/2025
Lonza CHF 430M 104M Dec/2024
McKesson USD 1.66B 159M Dec/2025
Merck EUR 1.21B 180M Sep/2025
Merck USD 6.24B 318M Dec/2025
Mettler Toledo International USD 351.93M 57.73M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Quest Diagnostics USD 386M 0 Dec/2025
Repligen USD 12.68M 6.72M Sep/2025
Revvity USD 145.83M 47.49M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Supernus Pharmaceuticals USD -60.18M 72.32M Sep/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
UnitedHealth USD 3.26B 1.06B Dec/2025
Waters USD 270.52M 78.4M Dec/2025
West Pharmaceutical Services USD 162.5M 5.1M Dec/2025